StimOxyGen, a Derry, Northern Eire, UK-based firm growing most cancers therapies, raised £1.5M in funding
The spherical was led by DSW Ventures, with co-investment from QUBIS and Co-Fund NI managed by Clarendon, leveraging extra funding from Innovate UK’s Future Economic system Investor Partnership grant programme.
The corporate intends to make use of the funds to advance key preclinical research, scale-up manufacturing, and broaden its staff because it strikes in direction of medical translation.
A spin-out from Ulster College is led by CEO Sian Farrell, CSO Professor Anthony McHale, and Non-Government Director Dr Les Russell, StimOxyGen develops most cancers therapies delivering oxygen on to tumours. Its lead candidate enhances the effectiveness of therapies comparable to radiotherapy and immunotherapy, providing a possible lifeline for sufferers with aggressive cancers. The know-how instantly addresses this problem by rising tumour oxygenation, making resistant cancers extra responsive to plain therapies. Preclinical research have already demonstrated important tumour discount when utilized in mixture with radiotherapy, with promising outcomes throughout a number of most cancers sorts. The corporate goals to develop its lead asset as an adjunct remedy to radiotherapy, enhancing outcomes for sufferers who at present have few choices.
StimOxyGen will initially deal with pancreatic most cancers, a illness with a five-year survival charge of simply 13% and restricted therapy choices.
FinSMEs
11/03/2025
